Trump Makes Multiple Statements on Economy and International Relations, Covering Apple, Chip Tariffs, and the Ukraine Situation
ChainCatcher news, according to Golden Ten Data, Trump recently made remarks covering multiple fields. He mentioned that Apple (AAPL.O) CEO Cook will remain in good shape and stated that Apple "used to be elsewhere, but now is coming home."He praised Oracle (ORCL.N) as an impressive company and mentioned that OpenAI has an unlimited market. Trump also said that Google (GOOG.O) performed very well yesterday, praised the CEO of AMD (AMD.O), and mentioned that he supported Microsoft (MSFT.O) by holding its stock at the age of 28.
Trump also emphasized that tariffs will be imposed on chip companies that do not come to the United States, and tariffs on semiconductors will be introduced soon. He expects employment data in the coming year to be very impressive.
In terms of international relations, Trump stated that he will resolve the situation in Ukraine and will speak with Russian President Putin in the near future.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ—US Stock Market Updates—MYR Group, Spyre Therapeutics, AMD
Search string for querying individual stock trends: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Briefing": https://refini.tv/3dKUyB8 Reuters, October 6 - U.S. stock index futures rose on Tuesday as Treasury yields retreated from multi-year highs and oil prices declined, providing a bit of relief for investors ahead of the quarterly earnings season. ** MYR Group MYRG.O: Market Spotlight — Jefferies upgraded MYR Group to "Buy"; stock price rose nL4N45S0PK ** Spyre Therapeutics SYRE.O: Market Action — Spyre Therapeutics shares fell due to a $350 millions stock offering nL6N45S0PG ** AMD.O: Market Action — AMD shares rose on plans to increase chip supply nL4N45S0Q7 ** Constellation Energy CEG.O: Highlight — Alphabet reportedly close to signing a multi-year nuclear energy deal, Constellation Energy shares climbed nL6N45S0HX ** Nike NKE.N: Highlight — Berenberg downgraded Nike to "Sell"; shares declined nL6N45S0KB ** Option Care Health OPCH.O: Highlight — Option Care Health surged after reportedly receiving a buyout offer exceeding $5 billions nL4N45S0L5 ** Freshworks Inc FRSH.O: Market Action — Freshworks stock advanced as it is set to be added to the S&P SmallCap 600 nL4N45S0IT (For the convenience of non-English speakers, Reuters automatically translates its reports into various other languages. As automatic translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them solely for readers' convenience. Reuters is not responsible for any damage or loss caused by the use of automatic translation features.)
Top Premarket Decliners
07:38 AM EDT, 10/06/2026 (MT Newswires) -- Armada Acquisition Corp. II (XRPN) shares were down more than 16% in premarket activity Tuesday following a nearly 2% fall in the prior session. HeartSciences (HSCS) stock was 14% lower after a 1.4% gain in the prior session. WISeSat.Space (SAIQ) shares were down 13% after a 260% rise at the previous close. CTW (CTW) stock was 7% lower after remaining flat at Monday's close. Republic Power Group (RPGL) shares were down 4% after a regulatory filing showed that the company and its institutional investor mutually agreed to terminate an additional investment right, with Republic paying a $250,000 termination fee.

Oil prices fall below 100 yuan+Besent calls out, U.S. Treasury yields retreat from 2002 highs
U.S. Treasury yields have retreated from their highest levels since 2002.
BUZZ - Spyre Therapeutics shares tumble due to $350 million stock offering
On October 6, Spyre Therapeutics (SYRE.O) shares fell 4.1% to $88.90 in pre-market trading after the company priced a $350 million follow-on offering. The biotechnology firm announced late Monday that it was issuing approximately 4.1 million shares at $85 per share, an 8.3% discount to its last closing price. The company plans to use the net proceeds to advance its programs in gastroenterology, rheumatology, and dermatology, as well as to move a new project—SPY072—into later-stage development for the chronic skin disease hidradenitis suppurativa, among other uses. Jefferies, TD Cowen, Leerink, and Stifel are acting as joint book-running managers for the offering. On September 30, Merck’s (MRK.N) tulisokibart achieved success in a dermatology clinical trial, after which SYRE shares climbed about 5%. Analysts noted that the trial data supports SYRE's experimental candidate targeting the same signaling pathway. Headquartered in Waltham, Massachusetts, SYRE had around 88.2 million shares outstanding prior to the offering. As of Monday’s close, the stock had risen 183% year-to-date. According to LSEG data, 16 of 17 analysts rate the stock a “strong buy” or “buy,” with one analyst rating it “hold.” The median price target is $123. (For the convenience of non-English speakers, Reuters provides automated translations of its reports. Automated translations may contain errors or lack necessary context; Reuters makes no guarantee regarding the accuracy of machine translations and provides them for readers’ convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation.)
